LANGHORNE, Pa. / Dec 17, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference.
Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET
Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara
Location: Westin St. Francis, San Francisco, Elizabethan C Room
The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 30 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X: @SavaraPharma and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
| Last Trade: | US$3.04 |
| Daily Change: | -0.02 -0.49 |
| Daily Volume: | 298,231 |
| Market Cap: | US$524.570M |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
